The Department of Health and Human Services is recommending to the Drug Enforcement Administration that cannabis should be reclassified as a Schedule III controlled substance under federal law, according to a report by
Full Year 2023 Outlook (53 week year)
The Company's Full Year Outlook for 2023 is presented below and does not include any possible future charges from our business optimization that the Company has not committed
Guidance
The company today raised its FY24 revenue growth and EPS guidance.
The company increased its FY24 organic revenue growth guidance to 4.5% versus the prior range of 4.0% to 4.5%. The organic revenue
The company raised its full-year base organic revenue growth guidance. Adjusted EPS guidance remains unchanged but reflects increased base business earnings offset by the Surgical Implementation platform divestiture and
A SPAC merger linked to the media arm of former President Donald Trump continues to face setbacks since being announced in October 2021.
Here’s the latest.
https://www.federalreserve.gov/newsevents/pressreleases/monetary20230614a.htmRecent indicators suggest that economic activity has continued to expand at a modest pace. Job gains have been robust in recent months, and the